Monte Rosa Therapeutics, Inc. Accrued Liabilities and Other Liabilities
Monte Rosa Therapeutics, Inc. (GLUE) had Accrued Liabilities and Other Liabilities of $1.17 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Payables and Accruals
us-gaap:AccruedLiabilitiesAndOtherLiabilities · last filed 2026-08-06
- 2026-06-30: Accrued Liabilities and Other Liabilities $1.17M.
- 2026-03-31: Accrued Liabilities and Other Liabilities $1.24M.
- 2025-12-31: Accrued Liabilities and Other Liabilities $1.52M; Accrued Liabilities and Other Liabilities as first filed $1.58M.
- 2024-12-31: Accrued Liabilities and Other Liabilities $3.35M.
| Period end | Accrued Liabilities and Other Liabilities | Accrued Liabilities and Other Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $1.17M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $1.24M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $1.52M 10-Q · filed 2026-08-06 | $1.58M 10-K · filed 2026-03-17 |
| 2024-12-31 | $3.35M 10-K · filed 2026-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |